Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06117566
PHASE1/PHASE2

A Study of WX390 Combined With Toripalimab in Patients With Advanced Solid Tumors

Sponsor: Shanghai Jiatan Pharmatech Co., Ltd

View on ClinicalTrials.gov

Summary

The goal of this clinical trial is to evaluate the safety and preliminary efficacy of WX390 combined with Toripalimab in patients with advanced solid tumors. The main questions it aims to answer are: * the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of WX390; * safety and preliminary in combined therapy. Participants will be treated with WX390 orally and Toripalimab intravenously, and follow the efficacy and safety evaluation according to the protocol.

Official title: A Phase Ib/IIa Study to Evaluate the Safety and Preliminary Efficacy of WX390 Combined With Toripalimab in Patients With Advanced Solid Tumors

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

100

Start Date

2022-11-18

Completion Date

2025-11-09

Last Updated

2024-11-25

Healthy Volunteers

No

Conditions

Interventions

DRUG

WX390

WX390 tablet, once a day

DRUG

Toripalimab

240 mg, Day 1, every 3 weeks

Locations (1)

the first affiliated hospital of Jilin university

Changchun, Jilin, China